SEC FORM 13F-HR
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete. |
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F
FORM 13F COVER PAGE
|
| OMB APPROVAL |
| OMB Number: |
3235-0006 |
| Expires: |
Oct 31, 2018 |
| Estimated average burden |
| hours per response: |
23.8 |
|
|
| Report for the Calendar Year or Quarter Ended: |
09-30-2022 |
| Check here if Amendment |
|
Amendment Number: |
| This Amendment (Check only one.): |
|
is a restatement. |
|
|
adds new holdings entries. |
| Institutional Investment Manager Filing this Report: |
| Name: |
JOHNSON & JOHNSON |
| Address: |
ONE JOHNSON & JOHNSON PLZ |
|
|
NEW BRUNSWICK,
NJ
08933
|
| Form 13F File Number: |
028-20072 |
The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.
| Person Signing this Report on Behalf of Reporting Manager: |
| Name: |
Marc Larkins |
| Title: |
Secretary |
| Phone: |
732-524-1476 |
| Signature, Place, and Date of Signing: |
| /s/ Marc Larkins |
New Brunswick,
NJ
|
11-10-2022 |
| [Signature] |
[City, State] |
[Date] |
|
| Report Type (Check only one.): |
| X |
13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) |
| |
13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) |
| |
13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) |
| Form 13F Summary Page |
|
Report Summary: |
|
Number of Other Included Managers: |
2 |
|
|
|
Form 13F Information Table Entry Total: |
22 |
|
Form 13F Information Table Value Total: |
339,823 |
|
(thousands) |
|
| List of Other Included Managers: |
| Provide a numbered list of the name(s) and Form 13F file number(s)
of all institutional investment managers with respect to which this report is filed, other than the
manager filing this report. |
| [If there are no entries in this list, state “NONE” and omit the
column headings and list entries.] |
|
No. |
Form 13F File Number |
Name |
|
1 |
028-20073 |
Johnson & Johnson Innovation - JJDC, Inc. |
|
2 |
028-21422 |
Johnson & Johnson UK Treasury Co Ltd |
SEC FORM 13-F Information Table
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete. |
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F
FORM 13F INFORMATION TABLE
|
| OMB APPROVAL |
| OMB Number: |
3235-0006 |
| Expires: |
Oct 31, 2018 |
| Estimated average burden |
| hours per response: |
23.8 |
|
|
| COLUMN 1 |
COLUMN 2 |
COLUMN 3 |
COLUMN 4 |
COLUMN 5 |
COLUMN 6 |
COLUMN 7 |
COLUMN 8 |
|
|
|
VALUE |
SHRS OR |
SH/ |
PUT/ |
INVESTMENT |
OTHER |
VOTING AUTHORITY |
| NAME OF ISSUER |
TITLE OF CLASS |
CUSIP |
(x$1000) |
PRN AMT |
PRN |
CALL |
DISCRETION |
MANAGER |
SOLE |
SHARED |
NONE |
| Adicet Bio, Inc. |
COM |
007002108 |
10,366 |
728,944 |
SH |
|
DFND |
1 |
0 |
728,944 |
0 |
| Aldeyra Therapeutics, Inc. |
COM |
01438T106 |
2,108 |
394,834 |
SH |
|
DFND |
1 |
0 |
394,834 |
0 |
| Arrowhead Pharmaceuticals, Inc. |
COM |
04280A100 |
8,183 |
247,598 |
SH |
|
DFND |
1 |
0 |
247,598 |
0 |
| BiomX Inc. |
COM |
09090D103 |
725 |
2,133,402 |
SH |
|
DFND |
1 |
0 |
2,133,402 |
0 |
| Catalyst Biosciences, Inc. |
COM |
14888D208 |
34 |
66,951 |
SH |
|
DFND |
1 |
0 |
66,951 |
0 |
| Cue Health, Inc. |
COM |
229790100 |
16,702 |
5,548,864 |
SH |
|
DFND |
1 |
0 |
5,548,864 |
0 |
| CVRx, Inc. |
COM |
126638105 |
32,614 |
3,495,575 |
SH |
|
DFND |
1 |
0 |
3,495,575 |
0 |
| Fate Therapeutics, Inc. |
COM |
31189P102 |
75,725 |
3,379,064 |
SH |
|
DFND |
1 |
0 |
3,379,064 |
0 |
| Fusion Pharmaceuticals Inc. |
COM |
36118A100 |
11,048 |
3,670,516 |
SH |
|
DFND |
1 |
0 |
3,670,516 |
0 |
| Graybug Vision, Inc. |
COM |
38942Q103 |
47 |
49,547 |
SH |
|
DFND |
1 |
0 |
49,547 |
0 |
| Legend Biotech Corporation |
ADS |
52490G102 |
66,470 |
1,629,173 |
SH |
|
DFND |
1 |
0 |
1,629,173 |
0 |
| MeiraGTx Holdings plc |
COM |
G59665102 |
24,377 |
2,898,550 |
SH |
|
DFND |
1 |
0 |
2,898,550 |
0 |
| Nano-X Imaging Ltd. |
ORD SHS |
M70700105 |
2,207 |
192,429 |
SH |
|
DFND |
1 |
0 |
192,429 |
0 |
| PhaseBio Pharmaceuticals, Inc. |
COM |
717224109 |
283 |
1,607,044 |
SH |
|
DFND |
1 |
0 |
1,607,044 |
0 |
| Point Biopharma Global Inc. |
COM |
730541109 |
7,730 |
1,000,000 |
SH |
|
DFND |
1 |
0 |
1,000,000 |
0 |
| Procept BioRobotics Corporation |
COM |
74276L105 |
35,818 |
863,908 |
SH |
|
DFND |
1 |
0 |
863,908 |
0 |
| Protagonist Therapeutics Inc. |
COM |
74366E102 |
20,647 |
2,449,183 |
SH |
|
DFND |
1 |
0 |
2,449,183 |
0 |
| Senseonics Holdings, Inc. |
COM |
81727U105 |
72 |
54,621 |
SH |
|
DFND |
1 |
0 |
54,621 |
0 |
| Tracon Pharmaceuticals, Inc. |
COM |
89237H209 |
140 |
84,003 |
SH |
|
DFND |
1 |
0 |
84,003 |
0 |
| Vor Biopharma, Inc. |
COM |
929033108 |
4,277 |
1,074,658 |
SH |
|
DFND |
1 |
0 |
1,074,658 |
0 |
| Xencor, Inc. |
COM |
98401F105 |
19,435 |
748,062 |
SH |
|
DFND |
1 |
0 |
748,062 |
0 |
| SomaLogic, Inc. |
COM |
83444K105 |
815 |
281,052 |
SH |
|
DFND |
N/A |
0 |
281,052 |
0 |
